At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 3, 2026 at 16:15 ET
AnaptysBio reported strong Q4 and full-year 2025 financial results driven by a surge in Jemperli royalties and milestones from GSK, including a $75M milestone payment. Collaboration revenue more than doubled, and the company confirmed progress toward a Q2 2026 spin-off of its biopharma assets into First Tracks Biotherapeutics. Despite a net loss for the year, cash remains robust at $311.6M, and the royalty outlook is bullish with >$390M in annualized royalties expected by 2029.
- Collaboration revenue was $108.2M (Q4) and $234.6M (full year 2025), up from $43.1M and $91.3M in 2024.
- Jemperli achieved $1B in global sales in Nov 2025, triggering a $75M milestone payment to Anaptys.
- Jemperli royalties grew 103% YoY to $96.0M for the year, with a $1.4B annualized run rate in Q4.
- Anaptys expects >$390M in annualized Jemperli royalties by 2029 at GSK's peak sales guidance of >$2.7B.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access